Why did PHIO's EPS stagnate in recent quarters?

Phio Pharmaceuticals' EPS stagnation in recent quarters can be attributed to a combination of factors: 1. **Operating Expenses and Financing**: Phio Pharmaceuticals has seen a decrease in cash and cash equivalents, from $8,490,000 at the end of 2023 to $5,390,000 by the end of Q3 2024. This decrease is due to operating expenses and financing activities. Despite a reduction in general and administrative expenses, the company's net loss for the quarter was $1,524,000, improved from the previous year's $2,780,000. This indicates that while costs are being managed, the company is still facing financial challenges that affect its EPS. 2. **Research and Development**: The company's research and development expenses decreased to $644,000 in Q3 2024, down from $1,808,000 in the same quarter the previous year. This reduction is due to cost rationalization measures and the wind-down of preclinical studies. While this might seem positive in terms of cost management, it could also imply a slowdown in innovation and development of new products, which might impact future revenue and, consequently, EPS. In conclusion, Phio Pharmaceuticals' EPS stagnation is likely a result of a combination of reduced revenue and increased expenses. The company's financial performance is under pressure due to operational and financing factors, which need to be addressed to improve its financial health and potentially its EPS in the future.